
Christine M. Lovly, M.D., Ph.D.
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Ingram Associate Professor of Cancer Research
- Associate Professor of Medicine (Hematology/Oncology)
Phone
2220 Pierce Ave South
777 Preston Research Building
Nashville, TN 37232
Christine M. Lovly, M.D., Ph.D.
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Ingram Associate Professor of Cancer Research
- Associate Professor of Medicine (Hematology/Oncology)
(615) 936-3457
christine.lovly@vumc.org
2220 Pierce Ave South
777 Preston Research Building
Nashville, TN 37232
Research Program
Departments/Affiliations
Provider Information
Profile
Christine Lovly, M.D., Ph.D., is a physician-scientist with a special interest in thoracic malignancies. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer.
She received a B.A. in chemistry from Johns Hopkins University followed by M.D. and Ph.D. degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in the Department of Medicine, Division of Hematology-Oncology in July 2012.
Dr. Lovly has received independent grant funding from Uniting Against Lung Cancer and the Conquer Cancer Foundation of the American Society of Clinical Oncology. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). She is also deputy editor for the website My Cancer Genome,a Vanderbilt initiated, freely available website which aims to provide health care practitioners, patient, and advocates with up-to-date information regarding genetically informed cancer medicine.
Education
- M.D., Washington University, Saint Louis, Missouri (2006)
- Ph.D., Washington University, Saint Louis, Missouri (2006)
- B.A., Johns Hopkins University, Baltimore, Maryland (1997)
Postgraduate Training
- Resident in Internal Medicine, Vanderbilt University School of Medicine, Nashville, TN (2006-2008)
- Clinical Fellow in Hematology and Oncology , Vanderbilt University School of Medicine, Nashville, TN (2008-2012)
- Jim and Carol O'Hare Chief Fellow in Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, TN (2011-2012)
Research Emphasis
Lung Cancer, EGFR , ALK, kinase fusions, acquired resistance, targeted therapies, tyrosine kinase inhibitors (TKIs), genomics, EGFR mutation, Small Cell Lung Cancer, Liquid Biopsies, Structural Biology, Precision Medicine
Research Description
Publications
- Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res [print-electronic]. 2017 Jun 6/1/2017; 77(11): 2990-3000. PMID: 28416483, PMCID: PMC5467531, PII: 0008-5472.CAN-16-2300, DOI: 10.1158/0008-5472.CAN-16-2300, ISSN: 1538-7445.
- Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov [print-electronic]. 2017 Jun; 7(6): 575-85. PMID: 28274957, PMCID: PMC5457707, PII: 2159-8290.CD-16-1431, DOI: 10.1158/2159-8290.CD-16-1431, ISSN: 2159-8290.
- Lovly CM, Iyengar P, Gainor JF. Managing Resistance to EFGR- and ALK-Targeted Therapies. Am Soc Clin Oncol Educ Book. 2017; 37: 607-18. PMID: 28561721, PII: 176251, DOI: 10.14694/EDBK_176251, ISSN: 1548-8756.
- Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S256-S257. PMID: 27969449, PII: S1556-0864(16)30966-2, DOI: 10.1016/j.jtho.2016.09.017, ISSN: 1556-1380.
- Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res [print-electronic]. 2016 Nov; 4(11): 959-67. PMID: 27671167, PMCID: PMC5134329, PII: 2326-6066.CIR-16-0143, DOI: 10.1158/2326-6066.CIR-16-0143, ISSN: 2326-6074.
- Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin. Cancer Res [print-electronic]. 2016 Oct 10/1/2016; 22(19): 4837-47. PMID: 27252416, PII: 1078-0432.CCR-15-1915, DOI: 10.1158/1078-0432.CCR-15-1915, ISSN: 1078-0432.
- Qiao H, Lovly CM. Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. Cancer Discov. 2016 Oct; 6(10): 1084-6. PMID: 27698100, PMCID: PMC5117458, PII: 6/10/1084, DOI: 10.1158/2159-8290.CD-16-0910, ISSN: 2159-8290.
- Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S176-S177. PMID: 27676483, PII: S1556-0864(16)30726-2, DOI: 10.1016/j.jtho.2016.08.017, ISSN: 1556-1380.
- Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S209-S210. PMID: 27676529, PII: S1556-0864(16)30775-4, DOI: 10.1016/j.jtho.2016.08.066, ISSN: 1556-1380.
- Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology [editorial]. BMC Med. 2016 Jul 7/28/2016; 14(1): 110. PMID: 27469586, PMCID: PMC4964079, PII: 10.1186/s12916-016-0654-y, DOI: 10.1186/s12916-016-0654-y, ISSN: 1741-7015.